JCAR017: Additional Phase I/II data

Data from 42 evaluable pediatric patients with relapsed or refractory CD19+ ALL in the open-label, U.S. Phase I/II

Read the full 181 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE